Keyes Stange & Wooten Wealth Management LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Keyes Stange & Wooten Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 74.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,823 shares of the company's stock after acquiring an additional 2,059 shares during the quarter. Johnson & Johnson comprises approximately 0.5% of Keyes Stange & Wooten Wealth Management LLC's holdings, making the stock its 28th biggest position. Keyes Stange & Wooten Wealth Management LLC's holdings in Johnson & Johnson were worth $800,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Brighton Jones LLC boosted its stake in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Hudson Value Partners LLC boosted its stake in Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after purchasing an additional 1,022 shares during the period. Northwest & Ethical Investments L.P. boosted its stake in Johnson & Johnson by 40.7% in the 4th quarter. Northwest & Ethical Investments L.P. now owns 65,024 shares of the company's stock worth $9,404,000 after purchasing an additional 18,794 shares during the period. Douglass Winthrop Advisors LLC boosted its stake in Johnson & Johnson by 2.2% in the 4th quarter. Douglass Winthrop Advisors LLC now owns 109,409 shares of the company's stock worth $15,823,000 after purchasing an additional 2,357 shares during the period. Finally, Loudon Investment Management LLC boosted its stake in Johnson & Johnson by 1.7% in the 4th quarter. Loudon Investment Management LLC now owns 6,051 shares of the company's stock worth $875,000 after purchasing an additional 100 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.4%

NYSE JNJ traded up $0.67 during trading on Friday, hitting $163.65. The stock had a trading volume of 9,764,459 shares, compared to its average volume of 8,141,137. The stock has a market capitalization of $393.75 billion, a price-to-earnings ratio of 17.50, a P/E/G ratio of 2.19 and a beta of 0.41. The stock has a 50 day simple moving average of $154.29 and a 200 day simple moving average of $155.05. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.82 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday. Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday. Bank of America increased their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Finally, Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $172.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.